PubMed Health⌕ Search

Biomedical subjects

A Beaulieu

Publications and source records attributed to A Beaulieu.

9 recordsLinked to original sources
PubMed1992

Efficacy and tolerability of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis: a double-blind comparison with standard naproxen followed by an open-label trial.

One hundred and twenty-three patients with osteoarthritis (n = 50) or rheumatoid arthritis (n = 73) were enrolled in a 6-week, double-blind, randomized, controlled, parallel trial comparing enteric-coated naproxen with standard naproxen. Ninety-eight patients subsequently entered a 20-week, open-label trial of enteric-coated naproxen. The study demonstrated that naproxen in both its standard formulation and its new enteric-coated formulation is a highly effective form of therapy for osteoarthritis and rheumatoid arthritis. The tolerability profiles of the two formulations were similar in terms of the types of complaints reported. It is concluded that enteric-coated naproxen is an efficacious and well-tolerated formulation for the treatment of osteoarthritis and rheumatoid arthritis.

Adult↗
PubMed1992

Open-label tolerability study of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis.

Two hundred and ninety-six patients were enrolled in a 6-month, open-label tolerability study of enteric-coated naproxen in patients with rheumatoid arthritis (n = 174) and osteoarthritis (n = 122). Thirty percent of the patients were greater than 65 years of age. Under standard clinical prescribing conditions, enteric-coated naproxen 500 mg twice daily and 375 mg twice daily demonstrated an acceptable tolerability profile that was not different from what one would expect with standard naproxen.

Adult↗
PubMed1991

Topical autologous fibronectin in patients with recurrent corneal epithelial defects.

We designed a clinical trial to evaluate the effect of topical fibronectin (an adhesive protein) for prevention of recurrent corneal epithelial defects. Fifteen eyes (11 patients) with 2 documented epithelial defects within 12 weeks were included. Purity and biological activity of the prepared solutions of autologous plasma fibronectin were confirmed by sodium dodecyl-sulfate polyacrylamide gel electrophoresis and gelatin binding affinity, respectively. According to randomization, fibronectin or saline was given 5 times per day for 11 weeks to 1 eye of 11 patients. Eyes of 4 patients with bilateral disease were paired, 1 eye receiving fibronectin and the other saline. We examined the patients weekly. The following recurrence parameters were retained for analysis: number of weeks with an epithelial defect, area under recurrence curves, and number of weeks with discomfort. The randomized and paired data analyses suggest that topical autologous plasma fibronectin does not prevent recurrent corneal epithelial defects. We describe a patient who received two treatment courses bilaterally, each eye crossing over to the alternate medication after a first treatment course. The response to treatment of each eye appeared unassociated to the medication.

Administration, Topical↗
PubMed1990

Topical fibronectin and aprotinin for keratectomy wound healing in rabbits.

We evaluated the effect of fibronectin (an adhesive protein) and aprotinin (a protease inhibitor) as single or combined topical therapies for primary healing and prevention of recurrent corneal epithelial defects in the rabbit keratectomy wound model. The biological activity of the prepared solutions of rabbit plasma fibronectin (0.6 g/L) was suggested by in vitro assays of rabbit corneal epithelial cell adhesion and gelatin-binding affinity. In the first experiment, we compared fibronectin, albumin (a control nonadhesive protein), and saline. In the second and third experiments, fibronectin supplemented with aprotinin, aprotinin alone, and saline were compared; aprotinin was used at concentrations of 40 and 1000 kallikrein inactivating units (KIU) per mililiter. Our results suggest that topical fibronectin, 0.6 g/L, as well as aprotinin at 40- and 1000-KIU/mL concentrations, given alone or in combination, neither promote corneal epithelial wound healing nor prevent recurrent corneal epithelial defects in rabbit keratectomy wounds.

Administration, Topical↗
PubMed1979

IgG antibodies to double-stranded DNA in systemic lupus erythematosus sera. Independent variation of complement fixing activity and total antibody content.

Antibodies to double-stranded deoxyribonucleic acid were studied using the kinetoplast of Crithidia luciliae. Titers were determined separately by conventional immunofluorescence and the complement fluorescent technique, and results by the two methods were compared. Complement fixing activity varied independently of antibody content in whole serum and in IgG fractions. The well established correlation of complement fixing activity of this antibody with activity of lupus nephritis appears related, therefore, to qualitative rather than solely quantitative differences. This finding has important implications for the clinical assessment of patients with lupus, and investigations on the relationship of anti-DNA antibodies to lupus nephritis.

Antibodies↗
PubMedDate not supplied

Complement fixing antibodies to DS-DNA in systemic lupus erythematosus: a study using the immunofluorescent Crithidia luciliae method.

Crithidia luciliae, a hemoflagellate, was used in an immunofluorescent procedure to assay for antibodies to ds-DNA and their capacity to fix complement. Positive reactions with this method were limited to systemic lupus erythematosus patients, and sensitivity was comparable to the DNA binding assay. Complement fixing activity of antibodies to ds-DNA in 45 sera was determined using kinetoplast ds-DNA of Crithidia luciliae and an antiserum to C3. Complement fixing antibodies to ds-DNA were found in nearly all patients with documented active renal involvement and absent in nearly all patients with no, or inactive renal involvement.

Antibodies↗